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ABSTRACT
We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies
binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease.
Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker
patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma
therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.
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The coronavirus disease 2019 (COVID-19) is an infec-
tion caused by a newly discovered coronavirus, severe
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Together with SARS-CoV, which caused an
outbreak 17 years ago, SARS-CoV-2 is a member of
the subgenus Sarbecovirus. Both viruses express a gly-
coprotein termed spike protein (S), which mediates
viral entry into ACE2-positive host cells and is there-
fore the target of virus-neutralizing antibodies [1].
Another structural protein is the nucleocapsid protein
(NP), which is the most abundant and highly immu-
nogenic protein in coronaviruses, making it a suitable
candidate for diagnostic assays [2].
A study of antibody responses to SARS-CoV-2 in
patientswithCOVID-19 showed that nearly all patients
developed virus-specific antibodies within 2–3 weeks
after symptom onset [3]. Most serologic studies [3–5]
largely focused on binding antibodies to S and NP, but
not virus-neutralizing antibodies even though such
antibodies can be used therapeutically or prophylacti-
cally. Infusion of convalescent plasma has been used
to treat SARS-CoV-2 [6]. The measurement of neutra-
lizing antibodies is critical in finding the best donors
for plasma therapy, as well as being the gold standard
to evaluate vaccine responses. Recent vaccine and re-
infection studies in non-human primates suggest that
neutralizing antibodies are the correlate of protection
against SARS-CoV-2 [7,8]. Studies using convalescent
plasma to treat SARS-CoV-2 infectionswereperformed
only on a limited number of patients, and there were no
careful measurements of neutralizing antibody titers to
correlate with the clinical outcome [9]. This study
examines SARS-CoV-2 neutralizing antibodies in the
plasma of patients with different disease severity.
We studied 35 patients seen at Columbia University
IrvingMedical Center with PCR-confirmed SARS-CoV-
2 infection to assess their plasma antibody responses to
the virus. The age, sex, and time of blood collection after
onset of symptoms for each patient are summarized in
SupplementaryTable1.Patientswhorequiredhospitaliz-
ation in the intensive care unit (19) were categorized as
Severe,whereas thosewithmilder diseasewithorwithout
hospitalization (16) were categorized as Non-severe. As
expected, Severe cases were older (range 34–84; mean
58)thanNon-severecases(range20–58;mean38).Impor-
tantly, blood collection was taken, on average, about one
month after the onset of symptoms in both groups.
Immunoassays to quantify antibodies to SARS-CoV-
2 NP and S trimer were used to measure binding anti-
body titers in plasma of both Severe and Non-severe
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patients. Plasma titers of antibodies to SARS-CoV-2 NP
and S trimer were substantially higher in Severe
patients than in Non-severe patients (Figure 1a).
Specifically, for NP-directed antibodies, the reciprocal
plasma titers ranged from 292 to 37,099 (mean 5086)
for Severe cases and from 170 to 1376 (mean 615) for
Non-severe cases (Figure 1b). The mean plasma titer
was ∼8-fold higher in the Severe group, and this differ-
ence was statistically significant (p = 0.036). Similarly,
for S trimer-directed antibodies, the reciprocal plasma
titers ranged from 257 to 18,397 (mean 2985) for Severe
patients and from <100 to 1963 (mean 364) for Non-
severe patients (Figure 1b and Supplementary Table
1). The mean plasma titer was also ∼8-fold higher in
Figure 1. Antibody responses against SARS-CoV-2. (a) Plasma titers of binding antibodies to SARS-CoV-2 NP and S trimer in Severe
and Non-severe patients. (b) Comparison of the level of binding antibodies against SARS-CoV-2 between Severe and Non-severe
patients. (c) Plasma neutralizing activities against SARS-CoV-2 pseudovirus and live virus in Severe and Non-severe patients. (d )
Comparison of the level of neutralizing antibodies against SARS-CoV-2 between Severe and Non-severe patients. (e–f) Correlation
of SARS-CoV-2 live virus neutralization titers versus pseudovirus neutralization titers (e) and S trimer-binding antibody titers ( f ).
Lines in (b) and (d ) represent mean ± SEM and p values were calculated by two-tailed t-test. * p < 0.05; *** p < 0.001. In (e–f), the
Pearson correlation coefficient (r) and the probability p value were calculated using GraphPad Prism.
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the Severe group, and this difference was again statisti-
cally significant (p = 0.016).
Next, antibody neutralization assays against SARS-
CoV-2 pseudovirus and live virus (2019-nCoV/
USA_WA1/2020) were performed on plasma samples
from Severe and Non-severe patients. Overall, both
SARS-CoV-2 pseudovirus and live virus neutralization
titers were substantially higher in the plasma of Severe
patients compared to those of Non-severe patients
(Figure 1c). Specifically, in the SARS-CoV-2 pseudo-
virus assay, the reciprocal plasma neutralizing titers
ranged from <100 to 13,710 (mean 2545) for Severe
cases and from <100 to 1463 (mean 491) for Non-
severe cases (Figure 1d and Supplementary Table 1).
The mean pseudovirus neutralizing titer was ∼5-fold
higher in the Severe group, and this difference was
statistically significant (p = 0.015). Similarly, in the
SARS-CoV-2 live virus assay, the reciprocal plasma
titers ranged from 926 to 30,175 (mean 10,701) for
Severe patients and from <100 to 6884 (mean 1485)
for Non-severe patients (Figure 1d and Supplementary
Table 1). The mean live virus neutralizing titer was
∼7-fold higher in the Severe group, and this difference
was again statistically significant (p < 0.001).
A few other findings were notable. First, the plasma
neutralizing titers against the SARS-CoV-2 pseudovirus
correlated quite well with the titers obtained against the
live virus (Figure 1e). In addition, neutralizing titers cor-
related well with S trimer-binding antibody titers as
determined by quantitative immunoassay (Figure 1f).
The results of this study show that patients with severe
SARS-CoV-2 disease have more robust binding anti-
bodies tobothNPandStrimer (Figure1a,b).Functionally
active antibodies capable of virus neutralizationwere also
moreabundantinthesickerpatients(Figure1c,d).Thelat-
ter finding is reminiscent of the observation that HIV-1
broadly neutralizing antibodies were most commonly
found in patients with persistent viremia for a protracted
period [10]. There is evidence that patients with severe
SARS-CoV-2 infection have a higher viral load [5], and
perhaps a longer exposure to a greater abundance of
viral antigens is the basis for our findings. Regardless,
theresultsreportedhereindohaveimportantimplications
for donor selectionwhenpursuingplasma therapy or iso-
latingneutralizingmonoclonal antibodies.Of course, this
selection is best made by assessing virus-neutralizing
activity in the serumor plasma of potential donors.How-
ever, even an S trimer-based immunoassay could provide
useful guidance in choosing convalescent patients who
have the most robust neutralizing antibodies (Figure 1f).
The scientific community and general public eagerly
awaitdatathatcouldanswerwhetherhavingvirus-neutra-
lizing antibodies is equivalent tohavingprotective immu-
nity. The strong correlations observed here between
antibodies that bind the S trimer and antibodies that neu-
tralize the virus could facilitate future studies to under-
stand what constitutes immunity against SARS-CoV-2.
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